146 related articles for article (PubMed ID: 16531255)
1. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
[TBL] [Abstract][Full Text] [Related]
2. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
3. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
6. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
Lowenstein H; Shah A; Chant A; Khan A
Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
Grdisa M
Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
[TBL] [Abstract][Full Text] [Related]
8. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
Dyer MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation.
van der Velden VH
Haematologica; 2006 Mar; 91(3):291A. PubMed ID: 16531248
[No Abstract] [Full Text] [Related]
10. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract][Full Text] [Related]
12. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K
Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
14. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.
Angiolillo AL; Yu AL; Reaman G; Ingle AM; Secola R; Adamson PC
Pediatr Blood Cancer; 2009 Dec; 53(6):978-83. PubMed ID: 19637330
[TBL] [Abstract][Full Text] [Related]
16. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
Shah A; Lowenstein H; Chant A; Khan A
Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
[TBL] [Abstract][Full Text] [Related]
17. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
18. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
[TBL] [Abstract][Full Text] [Related]
19. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
Lockwood CM; Hale G; Waldman H; Jayne DR
Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
[TBL] [Abstract][Full Text] [Related]
20. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]